Atopic Dermatitis Yardstick update

Mark Boguniewicz; Luz Fonacier; Emma Guttman-Yassky; Peck Y. Ong; Jonathan I. Silverberg

doi:10.1016/j.anai.2023.03.010

Atopic Dermatitis Yardstick update

Mark Boguniewicz, Luz Fonacier, Emma Guttman-Yassky, Peck Y. Ong, Jonathan I. Silverberg

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Original language	English
Pages (from-to)	811-820
Number of pages	10
Journal	Annals of Allergy, Asthma and Immunology
Volume	130
Issue number	6
DOIs	https://doi.org/10.1016/j.anai.2023.03.010
State	Published - Jun 2023

Access to Document

10.1016/j.anai.2023.03.010

Cite this

@article{50851bf987274f75abb085079e24bbab,

title = "Atopic Dermatitis Yardstick update",

author = "Mark Boguniewicz and Luz Fonacier and Emma Guttman-Yassky and Ong, {Peck Y.} and Silverberg, {Jonathan I.}",

note = "Funding Information: Disclosures: Dr Boguniewicz has served as an investigator for Regeneron, Sanofi and Incyte and a consultant for AbbVie, Eli Lilly, Janssen, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme. Dr Fonacier received research and educational grants (made to NYU Langone Hospital—Long Island) from Regeneron, Pfizer, and AstraZeneca, and is a consultant for Regeneron, AbbVie, Pfizer, and Eli Lilly. Dr Guttman-Yassky received research grants (paid to the Icahn School of Medicine at Mount Sinai) from Boehringer-Ingelheim, Leo Pharma, Pfizer, Cara Therapeutics, UCB, Kyowa Kirin, RAPT, Amgen, GlaxoSmithKline, Incyte, Sanofi, Bristol-Myers Squibb, Aslan, Regeneron, Anaptysbio, Concert, and Janssen; and is a consultant for AbbVie, Almirall, Amgen, Aslan Pharmaceuticals, AstraZeneca, Biolojic Design, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Connect Pharma, DBV Technologies, Eli Lilly, EMD Serono, Evidera, Galderma, Gate Bio, Genentech, Incyte, Inmagene, Janssen Biotech, Kyowa Kirin, Leo Pharma, Merck, Pfizer, Q32 Bio, RAPT, Regeneron, Sanofi, SATO, Siolta, Target, UCB, and Ventyx. Dr Ong received research funding from Regeneron, Sanofi-Genzyme, Leo, and Incyte, and consulted for Incyte, AbbVie, and Janssen. Dr Silverberg received honoraria as a consultant and/or advisory board member for AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, Sidekick Health, and Union; speaker for AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; and institution received grants from Galderma and Pfizer. ",

year = "2023",

month = jun,

doi = "10.1016/j.anai.2023.03.010",

language = "English",

volume = "130",

pages = "811--820",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "6",

}

TY - JOUR

T1 - Atopic Dermatitis Yardstick update

AU - Boguniewicz, Mark

AU - Fonacier, Luz

AU - Guttman-Yassky, Emma

AU - Ong, Peck Y.

AU - Silverberg, Jonathan I.

N1 - Funding Information: Disclosures: Dr Boguniewicz has served as an investigator for Regeneron, Sanofi and Incyte and a consultant for AbbVie, Eli Lilly, Janssen, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme. Dr Fonacier received research and educational grants (made to NYU Langone Hospital—Long Island) from Regeneron, Pfizer, and AstraZeneca, and is a consultant for Regeneron, AbbVie, Pfizer, and Eli Lilly. Dr Guttman-Yassky received research grants (paid to the Icahn School of Medicine at Mount Sinai) from Boehringer-Ingelheim, Leo Pharma, Pfizer, Cara Therapeutics, UCB, Kyowa Kirin, RAPT, Amgen, GlaxoSmithKline, Incyte, Sanofi, Bristol-Myers Squibb, Aslan, Regeneron, Anaptysbio, Concert, and Janssen; and is a consultant for AbbVie, Almirall, Amgen, Aslan Pharmaceuticals, AstraZeneca, Biolojic Design, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Connect Pharma, DBV Technologies, Eli Lilly, EMD Serono, Evidera, Galderma, Gate Bio, Genentech, Incyte, Inmagene, Janssen Biotech, Kyowa Kirin, Leo Pharma, Merck, Pfizer, Q32 Bio, RAPT, Regeneron, Sanofi, SATO, Siolta, Target, UCB, and Ventyx. Dr Ong received research funding from Regeneron, Sanofi-Genzyme, Leo, and Incyte, and consulted for Incyte, AbbVie, and Janssen. Dr Silverberg received honoraria as a consultant and/or advisory board member for AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, Sidekick Health, and Union; speaker for AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; and institution received grants from Galderma and Pfizer.

PY - 2023/6

Y1 - 2023/6

UR - http://www.scopus.com/inward/record.url?scp=85151618657&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2023.03.010

DO - 10.1016/j.anai.2023.03.010

M3 - Article

C2 - 36931465

AN - SCOPUS:85151618657

SN - 1081-1206

VL - 130

SP - 811

EP - 820

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 6

ER -